Table 2 Clinical trials involving BRAF-targeted therapies in BRAF-mt colorectal cancer patients
From: Exploring the best treatment options for BRAF-mutant metastatic colon cancer
Therapeutic strategy | Regimen | n | ORR (%) | PFS (months) | Reference |
|---|---|---|---|---|---|
BRAF inhibitor | Vemurafenib | 21 | 5 | 2.1 | |
Vemurafenib | 10 | 0 | 4.5 | ||
Dabrafenib | 9 | 11 | NR | ||
Encorafenib | 18 | 0 | 4 | ||
BRAF inhibitor + MEK inhibitor | Dabrafenib + trametinib | 43 | 12 | 3.5 | |
BRAF inhibitor + anti-EGFR mAb | Vemurafenib + cetuximab | 27 | 4 | 3.7 | |
Encorafenib + cetuximab | 26 | 19.2 | 3.7 | ||
Encorafenib + cetuximab | 50 | 22 | 4.2 | ||
Vemurafenib + panitumumab | 15 | 13 | 3.2 | ||
Dabrafenib + panitumumab | 20 | 0 | 3.5 | ||
BRAF inhibitor + anti-EGFR mAb + MEK inhibitor | Dabrafenib + panitumumab + trametinib | 91 | 21 | 4.2 | |
Encorafenib + cetuximab + bimetinib | 29 | 41 | 8 | ||
BRAF inhibitor + anti-EGFR mAb + PI3K inhibitor | Encorafenib + cetuximab + alpelisib | 28 | 17.9 | 4.3 | |
Encorafenib + cetuximab + alpelisib | 52 | 27 | 5.4 | ||
BRAF inhibitor + anti-EGFR mAb + CT | Vemurafenib + cetuximab + irinotecan | 19 | 35 | 7.7 | |
Vemurafenib + cetuximab + irinotecan | 54 | 16 | 4.4 | ||
cetuximab + irinotecan | 52 | 4 | 2 |
